مالطا - الإنجليزية - Medicines Authority

p & d pharmaceuticals limited 38 woolmer way, bordon hampshire gu35 9qf, united kingdom - bromocriptine - tablet - bromocriptine 2.5 mg - anti-parkinson drugs

كندا - الإنجليزية - Health Canada

pro doc limitee - bromocriptine (bromocriptine mesylate) - tablet - 2.5mg - bromocriptine (bromocriptine mesylate) 2.5mg - ergot-derivative dopamine receptor agonists

كندا - الإنجليزية - Health Canada

pharmel inc - bromocriptine (bromocriptine mesylate) - tablet - 2.5mg - bromocriptine (bromocriptine mesylate) 2.5mg - ergot-derivative dopamine receptor agonists

كندا - الإنجليزية - Health Canada

pharmel inc - bromocriptine (bromocriptine mesylate) - capsule - 5mg - bromocriptine (bromocriptine mesylate) 5mg - ergot-derivative dopamine receptor agonists

مالطا - الإنجليزية - Medicines Authority

medochemie limited 1-10 constantinoupleos street, 3011 limassol, cyprus - bromocriptine mesilate - tablet - bromocriptine mesilate 2.5 mg - anti-parkinson drugs

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

santarus, inc. - bromocriptine mesylate (unii: ffp983j3od) (bromocriptine - unii:3a64e3g5zo) - bromocriptine 0.8 mg - cycloset is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. limitations of use - cycloset should not be used to treat type 1 diabetes or diabetic ketoacidosis. - limited efficacy data in combination with thiazolidinediones. - efficacy has not been confirmed in combination with insulin. cycloset is contraindicated in: - patients with known hypersensitivity to bromocriptine, ergot-related drugs, or any of the excipients in cycloset. - patients with syncopal migraine. bromocriptine increases the likelihood of a hypotensive episode among patients with syncopal migraine. loss of consciousness during a migraine may reflect dopamine receptor hypersensitivity. cycloset is a dopamine receptor agonist and may, therefore, potentiate the risk for syncope in these patients. - postpartum patients. serious and life-threatening adverse reactions have been reported with bromocriptine use in this population [see warnings and precautions (5.7), adverse reactions

نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - bromocriptine mesilate 2.87mg equivalent to bromocriptine 2.5 mg - tablet - 2.5 mg - active: bromocriptine mesilate 2.87mg equivalent to bromocriptine 2.5 mg excipient: colloidal silicon dioxide disodium edetate dihydrate lactose monohydrate magnesium stearate maize starch maleic acid pregelatinised maize starch

نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - bromocriptine mesilate 11.48mg - capsule - 10 mg - active: bromocriptine mesilate 11.48mg excipient: gelatin magnesium stearate

كندا - الإنجليزية - Health Canada

cobalt pharmaceuticals company - bromocriptine (bromocriptine mesylate) - capsule - 5mg - bromocriptine (bromocriptine mesylate) 5mg - ergot-derivative dopamine receptor agonists

كندا - الإنجليزية - Health Canada

cobalt pharmaceuticals company - bromocriptine (bromocriptine mesylate) - tablet - 2.5mg - bromocriptine (bromocriptine mesylate) 2.5mg - ergot-derivative dopamine receptor agonists